Coadministration of ORAL midazolam and Symtuza is contraindicated due to potential for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression. Coadministration of PARENTERAL midazolam should be done with caution and in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.